

616-056.7

54.1

90

90 2- , ().
- : « - », 2021, 680 .
ISBN 978-5-98803-450-6

(). 2014

MUCOVISCIDOSIS (cystic fibrosis).

2nd edition, revised and expanded

(edited by N.Yu. Kashirskaya, N.I.Kapranov, E.I.Kondratyeva).

- Moscow: Publishing House «MEDPRAKTIKA-M», 2021, 680 p.

ISBN 978-5-98803-XXX-X

This monograph is a fundamental work on cystic fibrosis. Compared with the first edition, published in 2014, all the chapters have been updated and new ones added, in particular the organisation of palliative care in cystic fibrosis, which is raised for the first time. It begins with a brief historical excursus into the world of the scientific and clinical research that has taken place into the understanding of cystic fibrosis over the last few centuries. The book then outlines the current understanding of the molecular genetic aspects of the disease, modern diagnostic methods and neonatal screening. It examines microbiology and the epidemiology of infectious complications, as well as the pathogenesis and clinical course of the disease, modern approaches to therapy and rehabilitation. There are specific features on adult cystic fibrosis and many other issues. The monograph summarises the achievements of world science as well as the authors' own clinical experience - the list of whom has enlarged considerably in comparison with the first edition. The authors hope that the monograph will be useful to a wide variety of readers from scientific specialists to practicing physicians of various specialities to medical students and all of those upon whom the struggle of improving the quality and increasing life expectancy of cystic fibrosis patients and the wellbeing of their families will depend.

© N.Yu. Kashirskaya, N.I.Kapranov, E.I.Kondratyeva. 2021

© Design: PH «MEDPRAKTIKA-M», 2021

ISBN 978-5-98803-XXX-X

	5
I.	17
1.2.	31
2.	-	52
2.1.	(CFTR). I CFTR,	52
2.2.	CFTR.....	53
2.2.	CFTR	53
2.2.2.	CFTR _r	55
2.2.3.	CFTR	59
2.2.4.	CFTR,	64
2.3.	CFTR	64
2.4.	CFTR	68
2.5. 11	CFTR —	71
2.6.	CFTR	73
2.7.	CFTR	81
2.8.	CFTR	83
2.9.	84
2.9.1.	- -	84
2.9.2.	- -	84
CFTR	84
2.9.3.	- - /	85
2.9.4.	86
2.10.	87
2.10.1.	- ,	88
2.10.2.	1 CFTR.....	89
2.10.3.	CFIR.....	92
2.1 I.	-	93
2.11.1.	97
2.12.	99
3.	1
3.1.	106
3.2.	12(1
[4.	125
4.1.	125
4.2.	133

5.		158
5.1.		158
5.2.		169
6.		185
6.1.		185
6.1.1.		187
6.1.2.		188
6.2.		191
6.2.1.		189
6.2.2.		191
7.		195
7.1.		195
7.2.		202
7.2.1.		202
7.2.2.		224
7.2.3.		240
7.3.	-	273
7.3.1.		273
7.3.2.		286
7.4.		291
7.4.1.		291
7.4.2.		299
7.5.	(,)	316
7.6.	(, ,)	348
8.		360
8.1.		360
8.2.		367
8.3.		379
(-)		381
8.4.		388
8.5.		406
9.		406
9.1.		426
9.2.		437
9.3.		438
9.3.1.		441
9.3.2.	<i>S.aureus</i>	444
9.3.3.	<i>.aeruginosa</i>	458
9.3.4.	<i>Burkholderia</i>	459
9.3.5.	<i>Achromobacter</i>	459
9.3.6.	<i>Stenotrophomonas maltophilia</i>	460
9.3.7.	(non-tuberculosis mycobacteria)	461
9.3.8.	<i>Aspergillus fumigatus</i>	474
9.4.		492
9.5.		506
9.6.		526
9.7.	()	

10.	530
10.1.	530
2.	553
10.3.	566
10.4.	575
II.	587
12.	606
13.	627
13.1.	627
13.2.	635
14.	647
14.1.		647
14.2.	-	652
14.3.	659
14.4.	-	672